Arq. Bras. Cardiol. 2021; 117(3): 561-598

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021

Marcus V. Simões ORCID logo , Fabio Fernandes ORCID logo , Fabiana G. Marcondes-Braga ORCID logo , Philip Scheinberg, Edileide de Barros Correia ORCID logo , Luis Eduardo P. Rohde ORCID logo , Fernando Bacal ORCID logo , Silvia Marinho Martins Alves ORCID logo , Sandrigo Mangini ORCID logo , Andréia Biolo ORCID logo , Luis Beck-da-Silva ORCID logo , Roberta Shcolnik Szor ORCID logo , Wilson Marques Junior, Acary Souza Bulle Oliveira ORCID logo , Márcia Waddington Cruz ORCID logo , Bruno Vaz Kerges Bueno ORCID logo , Ludhmila Abrahão Hajjar ORCID logo , Aurora Felice Castro Issa ORCID logo , Felix José Alvarez Ramires ORCID logo , Otavio Rizzi Coelho Filho ORCID logo , André Schmidt ORCID logo , Ibraim Masciarelli Francisco Pinto, Carlos Eduardo Rochitte ORCID logo , Flávio Henrique Valicelli, Marcelo Luiz Campos Vieira, Cláudio Tinoco Mesquita ORCID logo , Celso Dario Ramos, José Soares-Junior, Minna Moreira Dias Romano ORCID logo , Wilson Mathias Junior ORCID logo , Marcelo Iório Garcia Junior, Marcelo Westerlund Montera, Marcelo Dantas Tavares de Melo, Sandra Marques e Silva, Pedro Manoel Marques Garibaldi, Aristóteles Comte de Alencar Neto, Renato Delascio Lopes ORCID logo , Diane Xavier de Ávila ORCID logo , Denizar Viana, José Francisco Kerr Saraiva ORCID logo , Manoel Fernandes Canesin ORCID logo , Glaucia Maria Moraes de Oliveira ORCID logo , Evandro Tinoco Mesquita ORCID logo

DOI: 10.36660/abc.20210718

1. Introduction

Significant advances in understanding cardiac amyloidosis (CA) have been made in recent years, leading to a thorough reformulation of its clinical significance. In addition to convincing evidence that CA is a relatively common cause of heart failure with preserved ejection fraction (HFpEF), we are witnessing the emergence of specific therapies that can change the course of the disease and prolong the survival of affected patients.

In parallel, relevant advances in cardiovascular imaging techniques have greatly contributed to earlier and more accurate identification of the disease. Cardiac scintigraphy with bone-seeking radiotracers has allowed non-invasive diagnosis of transthyretin (TTR) cardiac amyloidosis (ATTR-CA), eliminating the need for endomyocardial biopsy, which has greatly simplified the diagnostic flow.

[…]

Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis – 2021

Comments

Skip to content